In conclusion, our study demonstrated that LAT1 expression can be used as a prognostic marker for patients with NHL and targeting LAT1 by JPH203 can be a novel therapeutic modality for NHL. The gene discussed is LAT; the disease is non-Hodgkin lymphoma.